Emcor vs Legence
EME and LGN side by side, both in construction special trade contractors. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EME and LGN compare
Emcor is the larger company, worth 7.6 times as much as Legence ($28.9B against $3.8B).
Legence grew revenue faster over the last twelve months (84.2% versus 22.1% for Emcor).
Emcor keeps more of each dollar of sales as profit, with a net margin of 7.8% compared with 1.0% at Legence.
Emcor pays a dividend yielding 0.24%; Legence does not pay one.
Emcor scores higher on the StockData Score (24 against 6 for Legence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EME | LGN |
|---|---|---|
| Size and price | ||
| Market cap | $28.9B | $3.8B |
| Share price | $659.36 | $35.00 |
| Change, 1 year | 2.5% | −4.6% |
| Change, 5 years | 409% | – |
| Beta (5Y) | 1.11 | 2.77 |
| Employees | 44K | 7,000 |
| StockData Score | ||
| Total score | 24 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 19.0× | – |
| P/S | 1.5× | 0.9× (better) |
| P/B | 6.8× | 5.5× (better) |
| EV/EBITDA | 13.6× (better) | 16.4× |
| P/FCF | 19.5× | 12.7× (better) |
| PEG | 0.37 | – |
| FCF yield | 5.1% | 7.9% (better) |
| Fair value | $645.80 | $19.81 |
| Margin of safety | −2.1% (better) | −76.7% |
| Growth | ||
| Revenue growth (TTM) | 22.1% | 84.2% (better) |
| Revenue growth, 5Y average | 14.1% | – |
| Net income growth (TTM) | 36.6% | – |
| EPS growth (TTM) | 39.2% | – |
| EPS growth, 5Y average | 63.7% | – |
| Profitability | ||
| Gross margin | 19.6% (better) | 19.1% |
| Operating margin | 10.4% (better) | 3.7% |
| Net margin | 7.8% (better) | 1.0% |
| FCF margin | 7.5% (better) | 6.9% |
| Return on equity | 40.6% (better) | 8.4% |
| Return on invested capital | 49.5% (better) | 9.3% |
| Financial health | ||
| Debt / equity | 0.00 | 1.51 (better) |
| Net debt / EBITDA | – | 2.32 |
| Interest coverage | – | 2.5× |
| Current ratio | 1.17 | 1.44 (better) |
| Altman Z-score | 5.85 (better) | 2.18 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.24% | – |
| Payout ratio | 4.2% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 25.6% | – |
| Buyback yield | 2.1% | – |
| Shareholder yield | 2.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 94.7% | 79.0% |
| Held by insiders | 0.74% | 47.1% |
| Insider net buying, 12 months | −$39.9M (better) | −$2.5B |
| Short interest, % of float | 1.7% | 4.5% |
Go deeper
- EME stock overview
- EME income statement
- EME valuation and score
- LGN stock overview
- LGN income statement
- LGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.